Orforglipron (Foundayo) is the most structurally innovative GLP-1 therapy to reach the US market in a decade — a small-molecule non-peptide GLP-1 receptor agonist that is chemically stable and fully absorbed with or without food, unlike semaglutide's oral Rybelsus which requires a narrow fasting window. FDA approved April 1, 2026, it is taken once daily as a standard tablet, eliminating all injection logistics: no refrigeration, sharps disposal, needle anxiety, or injection-site issues. In the ATTAIN trial, the 36mg dose delivered 12.4% weight loss — 33% less than Tirzepatide (Zepbound)'s 20.2% in SURMOUNT-5 — but for an estimated 35% of obesity patients who refuse injectables, this oral efficacy is transformative. Lilly launched it at $149 monthly self-pay, with Medicare Bridge coverage at ~$50 copay from July 1, 2026. Side effects include GLP-1-typical GI symptoms, possibly attenuated by steady oral absorption. Best for needle-averse patients, frequent travelers, or first-time GLP-1 users seeking simplicity.
Comments on "Orforglipron (Foundayo)"
Create a free account or sign in to join the discussion.
Sign in to join the conversation